The life sciences industry is entering 2025 in an environment of heightened financial pressure, geopolitical shifts, and evolving regulatory landscapes. As the CEO of a CRO deeply engaged in global clinical research, Dr. Sud observed several key trends that will shape industry-sponsored research this year. From funding constraints in biotech to rising patient costs and the strong U.S. dollar’s impact, sponsors and CROs alike will need to adapt rapidly. Here’s my perspective on the critical challenges and opportunities ahead.
1. Biotech Funding Challenges: A Lean Year for Startups
For early-stage biotech, 2024 was already a tough year, and 2025 isn’t looking any easier. Venture capital firms remain risk-averse, deploying capital cautiously, while IPOs in the biotech space have largely underperformed. Investors are demanding stronger clinical validation before committing funds, making early-stage financing harder to secure.
Cash-strapped biotech firms are cutting costs, delaying trials, and seeking out lower-cost geographies. Operational excellence—speed, cost efficiency, and AI-driven automation—will be the defining factor in winning contracts.
2. Uncertainty in NIH and Government Grants
The U.S. National Institutes of Health (NIH) remains a key funding source for academic and early-stage research. However, political and economic factors have introduced uncertainty into government-backed grants. Budget constraints and shifting political priorities may impact NIH’s ability to fund new projects at prior levels.
This uncertainty extends to Europe as well. The EU’s Horizon funding faces pressures, and many governments are prioritizing defense and energy over life sciences research.
For industry-sponsored research, this creates an opportunity. As government-backed funding becomes unpredictable, biotech and pharma companies may need to shift more toward industry partnerships, collaborations, and private funding models. CROs with established sponsor relationships and strong business development pipelines will benefit.
3. Cost per Patient Continues to Rise
One of the most pressing concerns in 2025 is the rising cost of patient enrollment and retention. Inflation, regulatory complexities, and site-related expenses are driving up the per-patient cost in clinical trials. Some estimates suggest that industry trials in oncology, rare diseases, and cell and gene therapy have seen costs increase by over 20% in the past two years.
Biotechs must find ways to mitigate these costs. This includes:
• Decentralized Trials (DCTs): Expanding the use of home-based visits, wearables, and remote monitoring to reduce site costs.
• Globalised Site Selection: Moving studies to more cost-effective geographies such as Southeast Asia, Australia, Eastern Europe, and Latin America.
CROs that can help sponsors navigate these rising costs will have a strong competitive advantage.
4. Public Equity Markets Remain Tough for Biotech
The biotech sector has struggled with a weak public equity market for over two years, and 2025 will likely see continued volatility. Investors remain wary of companies with long development timelines, high burn rates, and uncertain reimbursement pathways.
This means fewer biotech IPOs, reduced liquidity, and a slowdown in early-stage funding rounds. The impact on industry-sponsored research will be:
• A shift toward later-stage clinical trials. More companies will prioritize Phase 2/3 trials that de-risk their assets rather than early exploratory studies.
• Increased pressure on CROs to work with financially stable clients. Cash flow management will be critical, as some sponsors may struggle to make payments.
• More strategic partnerships. Expect to see CROs and pharma companies structure milestone-based payment models and equity-for-services deals to ease funding pressures.
CROs that can help biotech sponsors conserve cash and streamline trial execution will be the preferred partners.
5. The Globalization of Clinical Trials: New Hotspots Emerge
With rising costs in the U.S. and Western Europe, sponsors are increasingly looking at alternative geographies for clinical trials. The next wave of globalization in clinical research will focus on Southeast Asia, Australia, Eastern Europe, and parts of Latin America.
Emerging markets offer several advantages:
• Lower cost per patient compared to the U.S. or EU.
• Faster patient recruitment due to treatment-naïve populations.
• Growing regulatory harmonization with ICH-GCP standards.
CROs with established networks in these regions will see an influx of studies moving out of traditional markets. However, regulatory challenges remain, and quality control will be a key differentiator.
6. The Shift Away from China-domiciled CROs and CDMOs
Geopolitical tensions, U.S. regulatory scrutiny, and supply chain concerns are pushing pharma and biotech companies to reduce reliance on Chinese CROs and CDMOs. The FDA’s increased oversight of data from China has further complicated trial approvals.
This is driving:
• A shift toward CROs in Southeast Asia, Australia, India, and Eastern Europe as alternative outsourcing hubs.
• More “nearshoring” for U.S. and EU-based biotechs, with trials moving back to domestic or friendly regions.
• Greater investment in U.S. and European manufacturing capacity for biologics, small molecules, and cell & gene therapy.
Conclusion: Biotechs Must Adapt to Win
2025 will be a year of financial constraints, global shifts, and rising trial costs for the biotech and pharma industry. CROs that continue with traditional, slow, and expensive models will struggle. The winners will be those that:
1. Run leaner teams to reduce costs and increase trial speed.
2. Expand into cost-effective geographies where better pricing for trials is offered.
3. Learn how to best access global R&D incentives to fund their trials
4. Utilise AI and real-time data analytics to optimize site selection, patient recruitment, and monitoring to limit their expenditure on clinical trial execution.
Also Read: Innovative Technologies Changing the Game for B2B Startups
